| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2024 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3448 | RENSSELAER | USA | R01NS123568 | Cell Type and Regional Vulnerability in Frontotemporal Dementia | 000 | 2 | NIH | 12/11/2024 | $607,905 |
| | 2025 | 2023 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3448 | RENSSELAER | USA | R21GM140328 | Developing Antibody-Oligonucleotide Bridges to Simplify Single Cell Spatial Transcriptomics | 000 | 2 | NIH | 4/14/2025 | $0 |
| | 2025 | 2023 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3448 | RENSSELAER | USA | S10OD034295 | High-density microelectrode array | 000 | 1 | NIH | 4/23/2025 | $0 |
| | 2025 | 2021 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3448 | RENSSELAER | USA | RF1NS123568 | Cell Type and Regional Vulnerability in Frontotemporal Dementia | 000 | 1 | NIH | 12/11/2024 | -$607,905 |
| | 2025 | 2020 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3448 | RENSSELAER | USA | U01EY030581 | Transplantation of Adult, Tissue-Specific RPE Stem Cells as Therapy for Non-exudative Age-Related Macular Degeneration AMD | 000 | 2 | NIH | 3/24/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $6,413,724 ) |
| | 2024 | 2024 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3448 | RENSSELAER | USA | U01AG072464 | Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions | 004 | 4 | NIH | 9/25/2024 | $0 |
| | 2024 | 2024 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3448 | RENSSELAER | USA | UH3EY031810 | Phase1/2a Clinical Trial of RPESC-derived RPE Transplantation as Therapy for Non-exudative Age-related Macular Degeneration | 000 | 5 | NIH | 8/22/2024 | $634,049 |
| | 2024 | 2024 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3448 | RENSSELAER | USA | R61NS138655 | Human iPSC model of Cerebro-Vascular Interactions in ADRD | 000 | 1 | NIH | 8/15/2024 | $1,931,965 |
| | 2024 | 2024 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3448 | RENSSELAER | USA | U01AG072464 | Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions | 002 | 4 | NIH | 8/27/2024 | $422,406 |
| | 2024 | 2024 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3448 | RENSSELAER | USA | U01AG072464 | Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions | 001 | 4 | NIH | 6/19/2024 | $1,573,956 |
| | 2024 | 2024 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3448 | RENSSELAER | USA | U01AG072464 | Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions | 003 | 4 | NIH | 9/17/2024 | $0 |
| | 2024 | 2024 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3448 | RENSSELAER | USA | R01NS123568 | Cell Type and Regional Vulnerability in Frontotemporal Dementia | 000 | 2 | NIH | 8/12/2024 | $663,462 |
| | 2024 | 2024 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3452 | RENSSELAER | USA | R01EY032138 | Characterizing Human RPE Cell Proliferation to Advance Endogenous Regeneration | 000 | 4 | NIH | 11/30/2023 | $526,346 |
| | 2024 | 2024 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3452 | RENSSELAER | USA | R35NS097277 | Defining Characteristics of Cortical Progenitor Cells over Time in Mouse and Human | 001 | 8 | NIH | 4/10/2024 | $47,739 |
| | 2024 | 2024 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3452 | RENSSELAER | USA | R35NS097277 | Defining Characteristics of Cortical Progenitor Cells over Time in Mouse and Human | 000 | 8 | NIH | 11/30/2023 | $613,801 |
| | 2024 | 2023 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3452 | RENSSELAER | USA | U01AG072464 | Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions | 000 | 3 | NIH | 11/9/2023 | $0 |
| | 2024 | 2021 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3448 | RENSSELAER | USA | R01EY029281 | Characterization of human RPE subpopulations at the single cell level | 000 | 4 | NIH | 2/26/2024 | $0 |
| | 2024 | 2021 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3448 | RENSSELAER | USA | R01AG056293 | iPSC Modeling of AD Using Progerin | 000 | 5 | NIH | 12/21/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $4,042,618 ) |
| | 2023 | 2023 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3452 | RENSSELAER | USA | U01AG072464 | Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions | 002 | 3 | NIH | 6/22/2023 | $93,149 |
| | 2023 | 2023 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3452 | RENSSELAER | USA | UH3EY031810 | Phase1/2a Clinical Trial of RPESC-derived RPE Transplantation as Therapy for Non-exudative Age-related Macular Degeneration | 001 | 4 | NIH | 8/23/2023 | $638,369 |
| | 2023 | 2023 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3452 | RENSSELAER | USA | S10OD034295 | High-density microelectrode array | 000 | 1 | NIH | 3/17/2023 | $239,841 |
| | 2023 | 2023 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3452 | RENSSELAER | USA | U01AG072464 | Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions | 001 | 3 | NIH | 6/21/2023 | $1,603,401 |
| | 2023 | 2023 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3452 | RENSSELAER | USA | R21GM140328 | Developing Antibody-Oligonucleotide Bridges to Simplify Single Cell Spatial Transcriptomics | 000 | 2 | NIH | 2/9/2023 | $217,500 |
| | 2023 | 2023 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3452 | RENSSELAER | USA | R01EY032138 | Characterizing Human RPE Cell Proliferation to Advance Endogenous Regeneration | 001 | 3 | NIH | 3/6/2023 | $56,835 |
| | 2023 | 2023 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3452 | RENSSELAER | USA | R01EY032138 | Characterizing Human RPE Cell Proliferation to Advance Endogenous Regeneration | 000 | 3 | NIH | 12/1/2022 | $511,523 |
| | 2023 | 2023 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3452 | RENSSELAER | USA | R35NS097277 | Defining Characteristics of Cortical Progenitor Cells over Time in Mouse and Human | 001 | 7 | NIH | 11/23/2022 | $682,000 |
| | 2023 | 2022 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3452 | RENSSELAER | USA | U01AG072464 | Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions | 000 | 2 | NIH | 2/16/2023 | $0 |
| | 2023 | 2022 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3452 | RENSSELAER | USA | R35NS097277 | Defining Characteristics of Cortical Progenitor Cells over Time in Mouse and Human | 000 | 6 | NIH | 10/18/2022 | $0 |
| | 2023 | 2022 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3452 | RENSSELAER | USA | UH3EY031810 | Phase1/2a Clinical Trial of RPESC-derived RPE Transplantation as Therapy for Non-exudative Age-related Macular Degeneration | 000 | 3 | NIH | 7/12/2023 | $0 |
| | 2023 | 2020 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3452 | RENSSELAER | USA | U01EY030581 | Transplantation of Adult, Tissue-Specific RPE Stem Cells as Therapy for Non-exudative Age-Related Macular Degeneration AMD | 000 | 2 | NIH | 5/3/2023 | $0 |
| | 2023 | 2020 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3452 | RENSSELAER | USA | U01EY030581 | Transplantation of Adult, Tissue-Specific RPE Stem Cells as Therapy for Non-exudative Age-Related Macular Degeneration AMD | 000 | 2 | NIH | 5/3/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $3,916,459 ) (Continued on the next page) |
| | 2022 | 2022 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | ALBANY | NY | 12244-0001 | ALBANY | USA | U01AG072464 | Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions | 000 | 1 | NIH | 3/31/2022 | $31,078 |
| | 2022 | 2022 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3452 | RENSSELAER | USA | UH3EY031810 | Phase1/2a Clinical Trial of RPESC-derived RPE Transplantation as Therapy for Non-exudative Age-related Macular Degeneration | 001 | 3 | NIH | 8/29/2022 | $638,369 |
| | 2022 | 2022 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3452 | RENSSELAER | USA | U01AG072464 | Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions | 001 | 2 | NIH | 8/18/2022 | $1,635,911 |
| | 2022 | 2022 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3452 | RENSSELAER | USA | U01AG072464 | Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions | 002 | 2 | NIH | 8/19/2022 | $121,788 |
| | 2022 | 2022 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | ALBANY | NY | 12244-0001 | ALBANY | USA | R21GM140328 | Developing Antibody-Oligonucleotide Bridges to Simplify Single Cell Spatial Transcriptomics | 000 | 1 | NIH | 2/22/2022 | $261,000 |
| | 2022 | 2022 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | ALBANY | NY | 12244-0001 | ALBANY | USA | R01EY032138 | Characterizing Human RPE Cell Proliferation to Advance Endogenous Regeneration | 000 | 2 | NIH | 12/3/2021 | $506,889 |
| | 2022 | 2022 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | ALBANY | NY | 12244-0001 | ALBANY | USA | R01EY032138 | Characterizing Human RPE Cell Proliferation to Advance Endogenous Regeneration | 001 | 2 | NIH | 5/4/2022 | $39,424 |
| | 2022 | 2022 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | ALBANY | NY | 12244-0001 | ALBANY | USA | R35NS097277 | Defining Characteristics of Cortical Progenitor Cells over Time in Mouse and Human | 000 | 6 | NIH | 12/1/2021 | $535,502 |
| | 2022 | 2022 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | ALBANY | NY | 12244-0001 | ALBANY | USA | R35NS097277 | Defining Characteristics of Cortical Progenitor Cells over Time in Mouse and Human | 001 | 6 | NIH | 12/2/2021 | $87,000 |
| | 2022 | 2022 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | ALBANY | NY | 12244-0001 | ALBANY | USA | R35NS097277 | Defining Characteristics of Cortical Progenitor Cells over Time in Mouse and Human | 002 | 6 | NIH | 3/28/2022 | $59,498 |
| | 2022 | 2021 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3452 | RENSSELAER | USA | UH3EY031810 | Phase1/2a Clinical Trial of RPESC-derived RPE Transplantation as Therapy for Non-exudative Age-related Macular Degeneration | 000 | 2 | NIH | 3/11/2022 | $63,799 |
| | 2022 | 2021 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3452 | RENSSELAER | USA | R35NS097277 | Defining Characteristics of Cortical Progenitor Cells over Time in Mouse and Human | 005 | 5 | NIH | 9/16/2022 | $0 |
| | 2022 | 2020 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3452 | RENSSELAER | USA | UG3EY031810 | Phase1/2a Clinical Trial of RPESC-derived RPE Transplantation as Therapy for Non-exudative Age-related Macular Degeneration | 000 | 1 | NIH | 3/11/2022 | -$63,799 |
| | 2022 | 2020 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3452 | RENSSELAER | USA | U01EY030581 | Transplantation of Adult, Tissue-Specific RPE Stem Cells as Therapy for Non-exudative Age-Related Macular Degeneration AMD | 000 | 2 | NIH | 8/15/2022 | $0 |
| | 2022 | 2020 | REGENERATIVE RESEARCH FOUNDATION | 1 DISCOVERY DR | RENSSELAER | NY | 12144-3452 | RENSSELAER | USA | U01EY030581 | Transplantation of Adult, Tissue-Specific RPE Stem Cells as Therapy for Non-exudative Age-Related Macular Degeneration AMD | 000 | 2 | NIH | 8/15/2022 | $0 |
|
